Cypress Capital’s AIM ImmunoTech AIM Stock Holding History

Cypress Capital’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2	Closed	-$75	–	395
2024 Q2	$75	Buy	+2	New	+$85	﹤0.01%	380

Other funds holding AIM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cypress Capital's AIM Position: Q3 2024 in Review

Cypress Capital sold out of AIM ImmunoTech (AIM) in Q3 2024, closing a stake of 2 shares — an estimated $75 sold.

Cypress Capital first reported a position in AIM in Q2 2024 and held it in 1 quarter. The position peaked at $75 in Q2 2024. 30 funds tracked by Wall St. Rank hold AIM as of Q3 2024.

Cypress Capital reported no remaining AIM ImmunoTech position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 2 AIM ImmunoTech shares in Q3 2024, an estimated $75.
Cypress Capital first reported a position in AIM ImmunoTech in Q2 2024 and held it in 1 quarter.
Cypress Capital's AIM ImmunoTech position peaked at $75 in Q2 2024.
30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.